Showing results (21-30 of 34) with videos related to
Sort By:
Pageof 4
BMC Genomics|June 26, 2009
Impact of animal strain on gene expression in a rat model of acute cardiac rejectionKatherine J Deans, Peter C Minneci, Hao Chen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2018
FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid LeukemiaEmily Y Jen, Chia-Wen Ko, Jee Eun Lee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2020
Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic AnalysisKelly J Norsworthy, Flora Mulkey, Emma C Scott, et al.American Journal of Hematology|December 13, 2025
Real-World Outcomes and Treatment Patterns in Patients With Acute Myeloid Leukemia and TP53 Gene Mutation or 17p DeletionRebecca Bystrom, Laura L Fernandes, Joseph Wynne, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2025
FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 MutationAshley C Woods, E Dianne Pulte, Xin Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2021
Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level AnalysesKelly J Norsworthy, Xin Gao, Chia-Wen Ko, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2024
FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 MutationAshley C Woods, Kelly J Norsworthy, Moran Choe, et al.Leukemia Research|September 14, 2016
Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studiesKelly J Norsworthy, Eunpi Cho, Jyoti Arora, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2024
Perspectives on Drug Development for the Treatment of Chronic Myeloid Leukemia in Pregnant Patients and Patients Who Are BreastfeedingJorge E Cortes, Elisabetta Abruzzese, Elyce H Cardonick, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2022
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid LeukemiaKendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.Pageof 4